Targeting Aberrant STAT3 Signaling as a Therapeutic Strategy for Multiple Myeloma
The oncogenic transcription factor STAT3 is aberrantly activated in over 70% of human tumours, including Multiple myeloma (MM). The present studies use both genetic and chemical tools to validate STAT3 as a therapeutic target, and demonstrate the anti-MM activity of a novel small molecule STAT3 inhi...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/35594 |